Welcome to our dedicated page for Evofem Bioscienc news (Ticker: EVFM), a resource for investors and traders seeking the latest updates and insights on Evofem Bioscienc stock.
Evofem Biosciences, Inc. (OTC: EVFM) regularly issues news and updates focused on women’s sexual and reproductive health, its FDA-approved products, and its corporate strategy. Company press releases highlight developments around PHEXXI, a hormone-free, on-demand prescription contraceptive vaginal gel, and SOLOSEC, a single-dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
News items cover a range of topics, including quarterly and annual financial results, cost-of-goods initiatives, and progress on international expansion. For example, Evofem has announced licensing arrangements with Pharma 1 Drug Store in the Middle East and North Africa, regulatory submissions for PHEXXI and SOLOSEC in the United Arab Emirates, and steps toward commercialization in Gulf Cooperation Council states. These updates provide context on how the company is seeking to diversify and expand its revenue stream beyond the United States.
Evofem’s releases also describe marketing and educational campaigns such as the "Say Vagina" initiative, which the company presents as an effort to normalize clinical language and address stigma around vaginal health. Other news has detailed the impact of social media campaigns on traffic to the PHEXXI website, engagement from healthcare providers, and broader brand awareness.
In addition, investors can find news about corporate actions and governance, including information on a previously proposed merger with Aditxt, Inc. and its subsequent termination, reverse stock split authorization, and capital raises through notes and warrants. This news page aggregates such announcements so readers can follow product, regulatory, commercial, and corporate developments related to Evofem Biosciences and its EVFM stock symbol over time.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will participate in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, featuring a corporate presentation at 7:00 a.m. ET. The second is the Morgan Stanley Virtual Global Healthcare Conference on September 14, 2021, in a fireside chat at 12:30 p.m. ET. Both events will be webcast and available for 30 days on the company’s website. Evofem focuses on women's sexual and reproductive health, including innovative contraceptive solutions.
Evofem Biosciences (NASDAQ: EVFM) reported a net loss of $33.4 million, improving from $46.2 million in Q1 2021. Phexxi sales surged by 68% to $1.9 million, with a 47% increase in prescriptions and a 52% growth in prescriber base. Operating expenses fell by 6% to $43 million, despite a 17% rise in R&D costs to $8.5 million. A celebrity campaign is set to launch in September 2021 to boost brand awareness. Cash and equivalents stood at $47 million as of June 30, 2021. The company remains on track for the EVOGUARD trial completion by year-end.
Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on August 11, 2021, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. Participants can access the event live and via archived presentation at this link. For phone participation, dial (866) 503-5561 (U.S.) or (253) 336-2965, using conference ID 9190716. An audio replay will be available for 24 hours post-call. Evofem focuses on innovative women's health solutions, including its FDA-approved product Phexxi®.
Evofem Biosciences (NASDAQ: EVFM) reported strong growth for its hormone-free contraceptive Phexxi in Q2 2021, dispensing over 14,000 units and involving more than 5,400 healthcare providers. Notably, 60% of new users are aged 18 to 34, with many switching from hormonal methods. CEO Saundra Pelletier highlighted a growing trend among women prioritizing hormone-free options. Detailed metrics will be discussed in the upcoming earnings call in August, further solidifying Phexxi's position in women's reproductive health.
Evofem Biosciences (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:30 a.m. ET. The presentation will be available via live webcast and archived for 30 days. The company focuses on developing products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi, launched in September 2020. Evofem is also evaluating the EVO100 candidate for preventing specific STIs in an ongoing Phase 3 clinical trial, EVOGUARD.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced that CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on June 8, 2021, at 1:00 p.m. ET. The presentation will focus on the commercialization of Evofem's hormone-free contraceptive Phexxi®, the Phase 3 clinical trial for EVO100 to prevent chlamydia and gonorrhea in women, and other initiatives. Interested participants can pre-register for the presentation at ldmicrojune2021.mysequire.com.
Evofem Biosciences, Inc. (NASDAQ: EVFM) has successfully closed a public offering of 50 million shares of common stock, raising approximately $46.6 million after expenses. The offering included warrants for an additional 50 million shares, with the underwriter granted a 30-day option for an extra 7.5 million shares and warrants. The proceeds will fund commercialization efforts for Phexxi, ongoing clinical trials for EVO100, and general corporate purposes. The offering was conducted under Evofem's effective shelf registration statement, and all securities were sold by the company.
Evofem Biosciences, Inc. (NASDAQ: EVFM) announced the pricing of its underwritten public offering of 50 million shares of common stock and accompanying short-term warrants, priced at $1.00 per share. The offering is expected to generate gross proceeds of $50 million, with an additional $50 million possible from the full exercise of the warrants. The net proceeds will fund commercialization activities for Phexxi, the ongoing EVOGUARD Phase 3 trial for EVO100, and general corporate purposes. The offering is set to close on or about May 20, 2021.
Evofem Biosciences (NASDAQ: EVFM) announced a proposed underwritten public offering of common stock or pre-funded warrants, along with common warrants for each share sold. The offering is contingent on market conditions and may include a 30-day underwriter option for additional shares. Proceeds will be allocated to commercial activities for Phexxi, the ongoing EVOGUARD Phase 3 clinical trial, and general corporate purposes. The offering is made under an effective shelf registration statement filed with the SEC.
Evofem Biosciences (NASDAQ: EVFM) announced research findings on its investigational drug EVO100 aimed at preventing chlamydia and gonorrhea in women. These findings will be presented at the Virtual ISPOR 2021 conference from May 17 to 20, 2021. The study involved 21 women and highlighted the significance of product satisfaction and its correlation with adherence to EVO100. The pivotal Phase 3 trial, EVOGUARD, is ongoing with over 80 activated sites, expecting to complete enrollment by year-end 2021. Positive results may lead to a New Drug Application to the FDA by late 2022.